TY - JOUR
T1 - Brain glial activation in fibromyalgia – A multi-site positron emission tomography investigation
AU - Albrecht, Daniel S.
AU - Forsberg, Anton
AU - Sandström, Angelica
AU - Bergan, Courtney
AU - Kadetoff, Diana
AU - Protsenko, Ekaterina
AU - Lampa, Jon
AU - Lee, Yvonne C.
AU - Höglund, Caroline Olgart
AU - Catana, Ciprian
AU - Cervenka, Simon
AU - Akeju, Oluwaseun
AU - Lekander, Mats
AU - Cohen, George
AU - Halldin, Christer
AU - Taylor, Norman
AU - Kim, Minhae
AU - Hooker, Jacob M.
AU - Edwards, Robert R.
AU - Napadow, Vitaly
AU - Kosek, Eva
AU - Loggia, Marco L.
N1 - Funding Information:
The study was supported by the following funding sources: International Association for the Study of Pain Early Career Award (MLL), DoD-W81XWH-14-1-0543 (MLL), R01-NS094306-01A1 (MLL), R01-NS095937-01A1 (MLL), R21-NS087472-01A1 (MLL), R01-AR064367 (VN, RRE), R01-AT007550 (VN), Martinos Center Pilot Grant for Postdoctoral Fellows (DSA), Harvard Catalyst Advance Imaging Pilot Grant (JMH), P41RR14075, 5T32EB13180 (T32 supporting DSA), and P41EB015896. The Swedish part of the study received funding from Stockholm County Council (EK), Swedish research Council (K2013-52X-22199-01-3 and 2016-01556) (EK), (2013-9306) (JL), the Swedish Rheumatism Association (EK) and Fibromyalgiförbundet (EK, DK). The research was also funded from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no.602919 (EK, JL) and from a donation from the Lundblad family (EK).
Funding Information:
The study was supported by the following funding sources: International Association for the Study of Pain Early Career Award (MLL), DoD-W81XWH-14-1-0543 (MLL), R01-NS094306-01A1 (MLL), R01-NS095937-01A1 (MLL), R21-NS087472-01A1 (MLL), R01-AR064367 (VN, RRE), R01-AT007550 (VN), Martinos Center Pilot Grant for Postdoctoral Fellows (DSA), Harvard Catalyst Advance Imaging Pilot Grant (JMH), P41RR14075, 5T32EB13180 (T32 supporting DSA), and P41EB015896. The Swedish part of the study received funding from Stockholm County Council (EK), Swedish research Council (K2013-52X-22199-01-3 and 2016-01556) (EK), (2013-9306) (JL), the Swedish Rheumatism Association (EK) and Fibromyalgiförbundet (EK, DK). The research was also funded from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no.602919 (EK, JL) and from a donation from the Lundblad family (EK).
Publisher Copyright:
© 2018 The Authors
PY - 2019/1
Y1 - 2019/1
N2 - Fibromyalgia (FM) is a poorly understood chronic condition characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties. While mounting evidence suggests a role for neuroinflammation, no study has directly provided evidence of brain glial activation in FM. In this study, we conducted a Positron Emission Tomography (PET) study using [11C]PBR28, which binds to the translocator protein (TSPO), a protein upregulated in activated microglia and astrocytes. To enhance statistical power and generalizability, we combined datasets collected independently at two separate institutions (Massachusetts General Hospital [MGH] and Karolinska Institutet [KI]). In an attempt to disentangle the contributions of different glial cell types to FM, a smaller sample was scanned at KI with [11C]-L-deprenyl-D2 PET, thought to primarily reflect astrocytic (but not microglial) signal. Thirty-one FM patients and 27 healthy controls (HC) were examined using [11C]PBR28 PET. 11 FM patients and 11 HC were scanned using [11C]-L-deprenyl-D2 PET. Standardized uptake values normalized by occipital cortex signal (SUVR) and distribution volume (VT) were computed from the [11C]PBR28 data. [11C]-L-deprenyl-D2 was quantified using λ k3. PET imaging metrics were compared across groups, and when differing across groups, against clinical variables. Compared to HC, FM patients demonstrated widespread cortical elevations, and no decreases, in [11C]PBR28 VT and SUVR, most pronounced in the medial and lateral walls of the frontal and parietal lobes. No regions showed significant group differences in [11C]-L-deprenyl-D2 signal, including those demonstrating elevated [11C]PBR28 signal in patients (p's ≥ 0.53, uncorrected). The elevations in [11C]PBR28 VT and SUVR were correlated both spatially (i.e., were observed in overlapping regions) and, in several areas, also in terms of magnitude. In exploratory, uncorrected analyses, higher subjective ratings of fatigue in FM patients were associated with higher [11C]PBR28 SUVR in the anterior and posterior middle cingulate cortices (p's < 0.03). SUVR was not significantly associated with any other clinical variable. Our work provides the first in vivo evidence supporting a role for glial activation in FM pathophysiology. Given that the elevations in [11C]PBR28 signal were not also accompanied by increased [11C]-L-deprenyl-D2 signal, our data suggests that microglia, but not astrocytes, may be driving the TSPO elevation in these regions. Although [11C]-L-deprenyl-D2 signal was not found to be increased in FM patients, larger studies are needed to further assess the role of possible astrocytic contributions in FM. Overall, our data support glial modulation as a potential therapeutic strategy for FM.
AB - Fibromyalgia (FM) is a poorly understood chronic condition characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties. While mounting evidence suggests a role for neuroinflammation, no study has directly provided evidence of brain glial activation in FM. In this study, we conducted a Positron Emission Tomography (PET) study using [11C]PBR28, which binds to the translocator protein (TSPO), a protein upregulated in activated microglia and astrocytes. To enhance statistical power and generalizability, we combined datasets collected independently at two separate institutions (Massachusetts General Hospital [MGH] and Karolinska Institutet [KI]). In an attempt to disentangle the contributions of different glial cell types to FM, a smaller sample was scanned at KI with [11C]-L-deprenyl-D2 PET, thought to primarily reflect astrocytic (but not microglial) signal. Thirty-one FM patients and 27 healthy controls (HC) were examined using [11C]PBR28 PET. 11 FM patients and 11 HC were scanned using [11C]-L-deprenyl-D2 PET. Standardized uptake values normalized by occipital cortex signal (SUVR) and distribution volume (VT) were computed from the [11C]PBR28 data. [11C]-L-deprenyl-D2 was quantified using λ k3. PET imaging metrics were compared across groups, and when differing across groups, against clinical variables. Compared to HC, FM patients demonstrated widespread cortical elevations, and no decreases, in [11C]PBR28 VT and SUVR, most pronounced in the medial and lateral walls of the frontal and parietal lobes. No regions showed significant group differences in [11C]-L-deprenyl-D2 signal, including those demonstrating elevated [11C]PBR28 signal in patients (p's ≥ 0.53, uncorrected). The elevations in [11C]PBR28 VT and SUVR were correlated both spatially (i.e., were observed in overlapping regions) and, in several areas, also in terms of magnitude. In exploratory, uncorrected analyses, higher subjective ratings of fatigue in FM patients were associated with higher [11C]PBR28 SUVR in the anterior and posterior middle cingulate cortices (p's < 0.03). SUVR was not significantly associated with any other clinical variable. Our work provides the first in vivo evidence supporting a role for glial activation in FM pathophysiology. Given that the elevations in [11C]PBR28 signal were not also accompanied by increased [11C]-L-deprenyl-D2 signal, our data suggests that microglia, but not astrocytes, may be driving the TSPO elevation in these regions. Although [11C]-L-deprenyl-D2 signal was not found to be increased in FM patients, larger studies are needed to further assess the role of possible astrocytic contributions in FM. Overall, our data support glial modulation as a potential therapeutic strategy for FM.
KW - Astrocytes
KW - Chronic overlapping pain conditions
KW - Deprenyl-D2
KW - Fibromyalgia
KW - Functional pain
KW - MRI/PET
KW - Microglia
KW - Neuroimmunology
KW - Neuroinflammation
KW - Positron emission tomography
KW - TSPO
UR - http://www.scopus.com/inward/record.url?scp=85053820060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053820060&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2018.09.018
DO - 10.1016/j.bbi.2018.09.018
M3 - Article
C2 - 30223011
AN - SCOPUS:85053820060
SN - 0889-1591
VL - 75
SP - 72
EP - 83
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
ER -